ARDELYX, INC. Net Fee Amt
ARDELYX, INC. (ARDX) had Net Fee Amt of $5.10 thousand as of 2026-08-10, per its S-8 filed 2026-08-10.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-10
- 2026-08-10: Net Fee Amt $5.10K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-10 | $5.10K S-8 · filed 2026-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |